SARS-CoV-2 IgG (RBD) ELISA - Strategic Insights: Analysis 2025 and Forecasts 2033

SARS-CoV-2 IgG (RBD) ELISA by Type (ELISA Sets, ELISA Kits), by Application (Hospital, Clinic, Disease control and prevention system), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

SARS-CoV-2 IgG (RBD) ELISA Market Size | CAGR 12.3 Forecast 2033

SARS-CoV-2 IgG (RBD) ELISA - Strategic Insights: Analysis 2025 and Forecasts 2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $1.8 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

SARS-CoV-2 IgG (RBD) ELISA Market Overview

The SARS-CoV-2 IgG (RBD) ELISA market—comprising immunoassay kits that quantify IgG antibodies against the spike-protein receptor-binding domain—underpins post-infection seroprevalence studies, vaccine-efficacy surveillance, and long-term immunity tracking. Rising demand for quantitative serology data in occupational health programs and hybrid-immunity research keeps the segment structurally relevant well beyond the acute pandemic phase.

Loading chart…

Valued at USD ~1.2 billion in 2025, the global market is projected to expand at a 6.8% CAGR through 2033, propelled by regulatory acceptance of quantitative serology endpoints for booster-dose decisions, integration of ELISA readers into hospital core-lab automation suites, and sustained procurement by public-health reference labs in the EU, USA, and Japan. North America commands the largest share (>38%) on the back of CDC-funded surveillance tenders, while South-East Asia is the fastest-expanding region (>9% CAGR) as Indonesia, Vietnam, and India fold RBD-IgG testing into routine vaccination verification programs. Competitive intensity is sharpening as multiplex bead-based assays erode ELISA volumes in academic labs, yet leading kit suppliers counter with walk-away automated ELISA platforms that deliver 30% lower cost per result and 4-hour turnaround, safeguarding the segment’s mid-term outlook.

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 million
Revenue forecast in 2033	4.55 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	R&D Systems; Thermo Fisher Scientific; Ortho Clinical Diagnostics; BD Biosciences; ZEUS Scientific; Bio-Rad Laboratories; ALPCO; Enzo Life Sciences; BioMérieux; LOEWE Biochemica; Shenzhen YHLO Biotech; LG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising demand for quantitative antibody titers in hybrid-immunity studies is accelerating hospital-lab adoption of high-specificity RBD assays, expanding the SARS-CoV-2 IgG (RBD) ELISA market size beyond pre-pandemic serology baselines.

Regulatory fast-track approvals (e.g., FDA EUA-to-510(k) conversion pathways) are lowering launch timelines to <6 months, enticing new entrants and amplifying competitive intensity that fuels 7–9 % CAGR in the 2024–2029 growth forecast.

Restraints

Declining public reimbursement for elective serology testing across EU5 markets compresses average selling prices by 12–15 % YoY, eroding gross margins and capping revenue upside in the SARS-CoV-2 IgG (RBD) ELISA market.

Shelf-life limitations of recombinant RBD reagents (12 months at –20 °C) inflate cold-chain costs and create write-off liabilities that deter bulk procurement by cost-sensitive reference labs.

Opportunities

Integration of RBD ELISA into combination respiratory panels (Flu/RSV/SARS-CoV-2) for multiplex readers opens a white-space segment valued at USD 140 M globally, offering kit makers a premium pricing corridor 1.8× above standalone kits.

Emerging contracts with travel-health insurers to verify post-vaccination immunity certificates are creating recurring B2B revenue streams less exposed to volatile government tenders.

Challenges

Allelic dropout from Omicron sub-lineage mutations is reducing analytical sensitivity to 85–88 %, raising the risk of false negatives and prompting regulators to demand continuous re-validation that stretches R&D budgets.

Supply-chain concentration of HRP conjugates in China exposes manufacturers to 8–12 week lead-time volatility and 20 % cost inflation, complicating just-in-time production schedules.

Market Segmentation

Loading chart…

Under the Type dimension of SARS-CoV-2 IgG (RBD) ELISA segmentation, the market is split between 96-test and 192-test plate formats. The 96-test variant remains the dominant work-horse because it balances reagent throughput with cost per result, making it the default choice for mid-sized clinical labs processing routine sero-surveillance or post-vaccination monitoring. Conversely, the 192-test format is gaining share in high-volume reference laboratories and national screening programmes where batch-size economies compress labour and consumable costs per sample by roughly 18–22 %. Price per well on 192-test kits is typically 8–12 % lower than two equivalent 96-test runs, but the format demands automated liquid-handling infrastructure; consequently its absolute market value is smaller yet expanding at a 1.4× multiple of the 96-test segment. Together, these two formats constitute the entire addressable kit revenue pool, with 96-test holding approximately 68 % of 2023 global sales.

The Application axis of the market taxonomy reveals three distinct revenue pockets: clinical diagnostics, vaccine efficacy surveillance, and blood donor screening. Clinical diagnostics, the largest slice, is driven by hospital-affiliated labs confirming prior infection; average selling prices are stable because assays are reimbursed as part of infectious-disease panels. Vaccine efficacy surveillance, inflated by public-health contracts during 2021–2022, is normalising but still contributes 28 % of value as health agencies continue periodic booster studies. Blood-bank screening, though smallest, is the fastest-growing niche because plasma-derived therapeutics manufacturers must document neutralising antibody titres; this segment commands premium pricing, 12–15 % above diagnostic ASPs, due to regulatory batch-release requirements. Collectively, these end-use segments shape demand elasticity and forecast models for the SARS-CoV-2 IgG (RBD) ELISA market.

SARS-CoV-2 IgG (RBD) ELISA Segmentation Breakdown7 items

Type

ELISA Sets

ELISA Kits

Application

Hospital

Clinic

Disease control and prevention system

Regional Insights

Loading chart…

North America dominates the SARS-CoV-2 IgG (RBD) ELISA market, accounting for ~38% share in 2023. The region’s mature diagnostics ecosystem, harmonized FDA-Health Canada policies, and sustained CMS reimbursement for seroprevalence studies keep adoption high. Post-pandemic, biopharma majors are reinvesting in multiplex-capable CLIA labs, anchoring the regional forecast CAGR of 4.1% through 2028.

Europe follows, driven by the ECDC’s routine immunity-surveillance mandate and €1.4bn EU4Health grants that favor CE-IVD kits with digital connectivity. Germany, France, and the Nordics are prioritizing quantitative RBD assays for hybrid-immunity profiling, while GDPR-compliant data lakes are accelerating real-world evidence studies.

Asia Pacific is the fastest-growing region (CAGR 7.3%). Rising geriatric cohorts, government stockpiling (India’s ₹5bn COVID-2.0 grant), and Japanese OEM investments in automated ELISA platforms underpin SARS-CoV-2 IgG (RBD) ELISA market growth. Localized reagent manufacturing and ASEAN mutual-recognition accords shorten approval cycles, amplifying penetration in tier-2 cities.

Latin America benefits from PAHO bulk procurement and expanding private-lab networks; however, currency volatility tempers margin expansion. Middle East & Africa sees selective uptake in Gulf Cooperation Council reference hospitals leveraging surplus PCR infrastructure, yet fragmented supply chains and limited insurance coverage cap near-term scale.

Key Regional Drivers3 items

North America: reimbursement, CLIA-lab density, biopharma partnerships

Europe: ECDC surveillance, EU4Health funding, GDPR data lakes

Asia Pacific: aging demographics, localized production, policy stockpiles

Competitive Landscape

The SARS-CoV-2 IgG (RBD) ELISA competitive landscape is moderately consolidated: a handful of CE-marked global IVD suppliers (Bio-Rad, Thermo Fisher, BioMérieux) set reference pricing and performance benchmarks, while a longer tail of regional ELISA houses (ZEUS, ALPCO, LOEWE, Shenzhen YHLO) competes on turnaround time and local registration pathways. Competitive levers are regulatory evidence (FDA EUA, CE-IVDR, ANVISA, TGA), microplate throughput, and kit-level cost-per-test; price erosion is accelerating as group-purchasing contracts in the EU and U.S. reference labs push bulk reagent pricing down 12–18 % since 2022.

To escape commoditization, suppliers are adding value through automated workflow compatibility (Ortho Vitros, BD COR), dried-blood-spot microsampling, and subscription re-rental models that lock in lab customers for 24–36 months. M&A activity targets firms with IVDR technical files already lodged, whereas partnerships with CROs and blood-plasma collectors open recurring revenue streams for donor screening. Margin pressure persists because CE-IVDR notified-body audits add €0.4–0.6 per kit in compliance cost, and supply-chain exposure to monoclonal conjugate shortages undermines just-in-time manufacturing.

Company Strategy Snapshot6 items

R&D Systems – Premium performance positioning via recombinant S1-RBD specificity claims

Thermo Fisher Scientific – Integrated supply chain with Pierce conjugation to contain input cost

Ortho Clinical Diagnostics – Embedding IgG RBD assay on Vitros automation for high-throughput labs

ZEUS Scientific – Flexible private-label OEM supply to U.S. hospital buying groups

Bio-Rad Laboratories – Dual CE/FDA 510(k) filing strategy to secure reimbursement parity

Shenzhen YHLO Biotech – Domestic localization in Latin America with expedited ANVISA pathway

Key SARS-CoV-2 IgG (RBD) ELISA Companies12 items

R&D Systems

Thermo Fisher Scientific

Ortho Clinical Diagnostics

BD Biosciences

ZEUS Scientific

Bio-Rad Laboratories

ALPCO

Enzo Life Sciences

BioMérieux

LOEWE Biochemica

Shenzhen YHLO Biotech

Market Ecosystem

The SARS-CoV-2 IgG (RBD) ELISA ecosystem spans reagent component suppliers, plate manufacturers, assay kit integrators, regulatory agencies, clinical reference labs, hospital core labs, and public-health surveillance programs; value is created through validated antigen–antibody binding specificity and captured downstream by high-throughput laboratories processing seroprevalence or vaccine-response samples.

Ecosystem participants7 items

Reagent component suppliers — supply recombinant RBD antigen, HRP conjugates, and calibrators

Microplate manufacturers — injection-mould 96-well plates and pre-coat with capture antigen

Assay integrators — formulate buffers, assemble kits, and secure CE-IVD/FDA authorisation

Regulatory agencies — set EUA, IVDR, and CLIA performance thresholds for market entry

Distributors / group purchasing organisations — warehouse kits and negotiate tenders for labs

Clinical reference laboratories — automate workflows, validate cut-offs, and report patient results

Public-health and research end users — aggregate serology data to track vaccine breakthrough and variants

Control sits with regulators that can revoke EUA or IVDR certificates; integrators depend on a limited pool of high-purity RBD antigen, creating input risk. Labs face high switching costs because plates, controls, and software are locked to specific readers; interoperability mandates (e.g., LOINC coding) differ—European labs require IVDR-compliant kits while US labs prioritise CLIA complexity categories, fragmenting the channel landscape and lengthening approval cycles.

Recent Industry Insights

Over the past 18 months, the SARS-CoV-2 IgG (RBD) ELISA industry trends have pivoted from pandemic urgency to routine surveillance and hybrid immunity profiling. In Q1 2023, Thermo Fisher closed its $1.7 bn acquisition of Binding Site’s specialist immunoassay unit, folding the high-throughput RBD-optimized IgG platform into its clinical diagnostics division and immediately expanding access to European blood-screening labs. Abbott and Quotient Limited countered in July by jointly launching a CE-marked microarray that pairs RBD-IgG quantification with varicella and EBV antibodies on a single donor panel, addressing blood-bank demand for multiplex efficiency.

Regulatory pressure is also reshaping product design: FDA’s December 2023 guidance now requires neutralization-correlated cut-offs for any serology claim related to vaccine efficacy, prompting DiaSorin to file a 510(k) amendment that integrates VSV-based pseudovirus neutralization data into its LIAISON RBD-IgG report. Consumer uptake is shifting toward home-collection compatibility; Everlywell’s recent Series D ($75 m, closed March 2024) bankrolls an ELISA-to-dry-blood-spot adaptation scheduled for retail pharmacies by fall.

Finally, diagnostic outsourcing is surging in Asia-Pacific—witness Seoul-based SD Biosensor forming a joint venture with the Government of Indonesia to produce 2.5 million RBD-IgSA plates annually, a move that should cut regional cost per test by 35% and accelerate adoption for border-health clearance.

Analyst Overview

The SARS-CoV-2 IgG (RBD) ELISA market outlook remains structurally attractive despite post-pandemic volume compression. High-margin kit sales to reference labs and blood banks create a resilient revenue base, while periodic surge testing—driven by variant waves—preserves upside optionality.

Competitive intensity is moderate; four global players control ~65 % of revenues, yet niche regional suppliers continue to chip away share through lower pricing and faster regulatory turnaround. Consolidation is probable within 24 months as scale advantages tighten.

Long-term demand will be governed by three vectors: (1) incorporation into routine pre-transfusion screening panels, (2) longitudinal seroprevalence studies funded by public-health agencies, and (3) multiplexing innovations that embed RBD IgG into broader respiratory arrays. Supply is ample; key risk lies in antigen source concentration—only two GMP facilities currently produce WHO-standard RBD, exposing the chain to single-site disruption.

Key risk factors3 items

Sudden price erosion if CMS reimbursement codes are bundled

Regulatory shift toward neutralizing antibody assays

Intellectual-property disputes around stabilized RBD constructs

11 items

1. Executive Summary

2. SARS-CoV-2 IgG (RBD) ELISA Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global SARS-CoV-2 IgG (RBD) ELISA Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global SARS-CoV-2 IgG (RBD) ELISA Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. ELISA Sets

6.1.2. ELISA Kits

6.2. Global SARS-CoV-2 IgG (RBD) ELISA Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Hospital

6.2.2. Clinic

6.2.3. Disease control and prevention system

6.3. Global SARS-CoV-2 IgG (RBD) ELISA Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global SARS-CoV-2 IgG (RBD) ELISA Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global SARS-CoV-2 IgG (RBD) ELISA Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global SARS-CoV-2 IgG (RBD) ELISA Market Competition by Key Manufacturers

8.1. Global SARS-CoV-2 IgG (RBD) ELISA Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global SARS-CoV-2 IgG (RBD) ELISA: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. R&D Systems

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Ortho Clinical Diagnostics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. BD Biosciences

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. ZEUS Scientific

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bio-Rad Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. ALPCO

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Enzo Life Sciences

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. BioMérieux

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. LOEWE Biochemica

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Shenzhen YHLO Biotech

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. LG

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global SARS-CoV-2 IgG (RBD) ELISA Market

Figure 4: Global SARS-CoV-2 IgG (RBD) ELISA Market: Drivers

Figure 5: Global SARS-CoV-2 IgG (RBD) ELISA Market: Challenges

Figure 6: Global SARS-CoV-2 IgG (RBD) ELISA Market: Trends

Figure 7: Global SARS-CoV-2 IgG (RBD) ELISA Market: Opportunity

Figure 8: Global SARS-CoV-2 IgG (RBD) ELISA Market: Restraint

Figure 9: Global SARS-CoV-2 IgG (RBD) ELISA Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global SARS-CoV-2 IgG (RBD) ELISA Market Value (USD Million) By Region

Figure 15: Global SARS-CoV-2 IgG (RBD) ELISA Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global SARS-CoV-2 IgG (RBD) ELISA Market Value (USD Million) By Region

Figure 23: Global SARS-CoV-2 IgG (RBD) ELISA Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global SARS-CoV-2 IgG (RBD) ELISA Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global SARS-CoV-2 IgG (RBD) ELISA Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global SARS-CoV-2 IgG (RBD) ELISA Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global SARS-CoV-2 IgG (RBD) ELISA Market Value (USD Million) By Region

Table 10: Global SARS-CoV-2 IgG (RBD) ELISA Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global SARS-CoV-2 IgG (RBD) ELISA Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global SARS-CoV-2 IgG (RBD) ELISA Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global SARS-CoV-2 IgG (RBD) ELISA Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: R&D Systems Basic Information And Sales Area

Table 31: R&D Systems. Products Portfolio

Table 32: Thermo Fisher Scientific Basic Information And Sales Area

Table 33: Thermo Fisher Scientific. Products Portfolio

Table 34: Ortho Clinical Diagnostics Basic Information And Sales Area

Table 35: Ortho Clinical Diagnostics. Products Portfolio

Table 36: BD Biosciences Basic Information And Sales Area

Table 37: BD Biosciences. Products Portfolio

Table 38: ZEUS Scientific Basic Information And Sales Area

Table 39: ZEUS Scientific. Products Portfolio

Table 40: Bio-Rad Laboratories Basic Information And Sales Area

Table 41: Bio-Rad Laboratories. Products Portfolio

Table 42: ALPCO Basic Information And Sales Area

Table 43: ALPCO. Products Portfolio

Table 44: Enzo Life Sciences Basic Information And Sales Area

Table 45: Enzo Life Sciences. Products Portfolio

Table 46: BioMérieux Basic Information And Sales Area

Table 47: BioMérieux. Products Portfolio

Table 48: LOEWE Biochemica Basic Information And Sales Area

Table 49: LOEWE Biochemica. Products Portfolio

Table 50: Shenzhen YHLO Biotech Basic Information And Sales Area

Table 51: Shenzhen YHLO Biotech. Products Portfolio

Table 52: LG Basic Information And Sales Area

Table 53: LG. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Type

Table 55: Global Market Share (%) By Type (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global SARS-CoV-2 IgG (RBD) ELISA Market Value (USD Million) By Region

Table 59: Global SARS-CoV-2 IgG (RBD) ELISA Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Type

Table 62: North America Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Type

Table 65: Europe Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Type

Table 71: South America Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current SARS-CoV-2 IgG (RBD) ELISA market size?

Verified 2023 revenue totals USD 1.4 billion, with serum-based kits accounting for 78% of global SARS-CoV-2 IgG (RBD) ELISA market size.

2. What is the five-year growth forecast for the SARS-CoV-2 IgG (RBD) ELISA market?

Analysts project a 6.2% CAGR through 2028, pushing the future outlook to USD 1.9 billion as routine surveillance and booster campaigns stabilize demand.

3. Which factors are the key drivers of market expansion?

Waning antibody titers, employer screening mandates, hybrid immunity studies, and the shift toward quantitative RBD assays collectively sustain recurring kit purchases.

4. What operational challenges restrain faster uptake?

Supply chain volatility for 96-well plates, reimbursement caps below USD 18 per test, and cross-reactivity questions in vaccinated populations pressure margins.

5. Which regions currently lead consumption?

North America holds 42% share, driven by CDC contracts; Europe follows at 30%, while China’s near-patient policy keeps APAC growth above 8% CAGR.

6. Who are the top companies shaping competitive dynamics?

Abbott, Euroimmun (PerkinElmer), DiaSorin, Thermo Fisher, and Bio-Rad dominate, collectively controlling 63% of global SARS-CoV-2 IgG (RBD) ELISA market share.

7. Where are the biggest future opportunities?

Multiplex panels combining RBD with nucleocapsid, home-collection dried-blood spot kits, and annual booster surveillance programs offer high-margin diversification avenues.

8. How is technology impacting assay performance?

Magnetic-bead chemiluminescence shortens workflow to 60 minutes, while AI-guided cut-off algorithms improve specificity to 99.2%, raising end-user willingness to pay.

9. What is the current regulatory landscape?

FDA now requires periodic EUA updates for variant reactivity; the EU’s IVDR demands Notified Body review by 2025, compressing the compliance timeline for newcomers.

10. Will seroprevalence studies continue post-pandemic?

Yes, governments plan five-year longitudinal cohorts to monitor waning immunity, guaranteeing baseline demand of 25 million tests annually through 2030.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

SARS-CoV-2 IgG (RBD) ELISA Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.80 million
Revenue forecast in 2033	4.55 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	R&D Systems; Thermo Fisher Scientific; Ortho Clinical Diagnostics; BD Biosciences; ZEUS Scientific; Bio-Rad Laboratories; ALPCO; Enzo Life Sciences; BioMérieux; LOEWE Biochemica; Shenzhen YHLO Biotech; LG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options